Transhuman Capital
Overview
Transhuman Capital invests in therapeutics, medical devices, and other technologies that have the potential to fundamentally improve the human condition . The firm partners with seed through crossover stage biotechnology companies .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Evecxia Therapeutics | Jun 2020 | Series A | Co-investor |
| Ambros Therapeutics, Inc. | Dec 2025 | Series A | Co-investor |
| Kriya Therapeutics | May 2022 | Series C | Co-investor |
| Terran Biosciences | Feb 2024 | Series B | Co-investor |
| Retension Pharmaceuticals | Aug 2025 | Series B | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Transhuman Capital based?
Transhuman Capital is headquartered in Ann Arbor, Michigan, United States.
When was Transhuman Capital founded?
Transhuman Capital was founded in 2014.
How many portfolio companies does Transhuman Capital have?
Transhuman Capital has 7 portfolio companies in Caplight's dataset.
What are some companies in Transhuman Capital's portfolio?
Portfolio companies visible on Caplight include Evecxia Therapeutics, Ambros Therapeutics, Inc., Kriya Therapeutics, Terran Biosciences, Retension Pharmaceuticals.
What was Transhuman Capital's most recent investment shown here?
Transhuman Capital's most recent investment in this portfolio sample was in Ambros Therapeutics, Inc. in 2025.
What sectors does Transhuman Capital focus on?
Transhuman Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software.
What company stages does Transhuman Capital focus on?
Transhuman Capital typically invests at the Early stage.
What is Transhuman Capital's AUM?
Transhuman Capital's assets under management are estimated between $0.0 and $50.0M.